Advantages of interventional therapy In recent years, liver cancer has become one of the major diseases that endanger the society and human health, which brings great pain and distress to human beings. In order to reduce the incidence of liver cancer, interventional treatment for liver cancer is very necessary. The advantages of interventional treatment for liver cancer are as follows: 1) precise efficacy, successful treatment can see rapid decrease of AFP, shrinkage of tumor and reduction of pain; 2) scientific mechanism, the local drug concentration of interventional treatment is tens of times higher than that of systemic chemotherapy, and the blood supply of tumor is blocked, so the two-pronged treatment is effective and less toxic than systemic chemotherapy Interventional treatment for hepatocellular carcinoma is simple and easy to operate, safe and reliable; 4. It can be performed even for old and weak people and people with certain diseases, without general anesthesia and keeping awake; 5. Transhepatic artery cannulation chemoembolization (TACE) for hepatocellular carcinoma, which is also commonly called hepatocellular interventional therapy by many patients, is a kind of regional local chemotherapy by injecting anti-cancer chemotherapeutic drugs or embolic agents into the hepatic artery through the femoral artery cannula, which is currently the preferred method of non-open surgery for hepatocellular carcinoma and its efficacy has been confirmed. Among the treatment methods of hepatocellular carcinoma, vascular interventional therapy has the most clinical application. It is mainly selective hepatic arterial chemoembolization for hepatocellular carcinoma. The main physiological basis is that the blood supply of normal hepatocytes is 20%-25% from hepatic artery and 75%-85% from portal vein. In primary hepatocellular carcinoma, 90%-95% of the blood supply comes from the hepatic artery, which provides the anatomical basis for vascular interventional treatment of tumors in hepatocellular carcinoma. The specific technical methods of all three are the same, which is to puncture a small opening of about 3-5mm on the skin, insert a tube from the artery to the blood supplying artery of hepatocellular carcinoma, and then administer the drug through the catheter, the difference lies in the different drugs administered. Selective hepatic arterial infusion (TAI) therapy involves intra-arterial infusion of the drug through a catheter at a dose equal to or less than that administered intravenously. This results in higher local drug concentrations in the target cells and prolonged contact time with the lesion, and reduces the total systemic drug dose, resulting in improved efficacy and fewer side effects. The efficacy of chemotherapeutic drugs is positively correlated with the effective blood concentration of the drug at the tumor site and the time of drug-tumor contact. Selective hepatic artery embolization (TAE) is to selectively inject embolic agents into tumor blood vessels and tumor blood supply arteries through catheters to block tumor blood supply and close tumor blood vessel beds, thus inhibiting tumor growth. This is equivalent to “starving” the tumor to death. Commonly used embolization agents include gelatin sponge, ultra-liquidated iodine oil, sodium alginate microspheres, etc. Selective hepatic artery chemoembolization (TACE) is the administration of both chemotherapeutic drugs and embolic agents via catheter. The tumor is destroyed by both routes. Indications According to the NCCN American Cancer Treatment Guidelines, interventional therapy has been recognized as the treatment of choice for intermediate to advanced hepatocellular carcinoma. It adopts local targeted drug infusion, tumor vascular embolization and argon-helium cryoablation to focus on killing tumor cells, minimizing tumor load (reducing the number and volume of malignant tumors) and combining with anti-tumor angiogenic drugs, etc. It has achieved good therapeutic effects in clinical practice, effectively improving patients’ survival quality and prolonging survival time. It can also reverse the stage of liver cancer in some patients and convert unresectable liver cancer cases into resectable liver cancer cases.